These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 36819490)

  • 61. Platycodin D inhibits migration, invasion, and growth of MDA-MB-231 human breast cancer cells via suppression of EGFR-mediated Akt and MAPK pathways.
    Chun J; Kim YS
    Chem Biol Interact; 2013 Oct; 205(3):212-21. PubMed ID: 23867902
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Apatinib enhanced anti-tumor activity of cisplatin on triple-negative breast cancer through inhibition of VEGFR-2.
    Gao Z; Shi M; Wang Y; Chen J; Ou Y
    Pathol Res Pract; 2019 Jul; 215(7):152422. PubMed ID: 31079851
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Plasma exosomal miR-335-5p serves as a diagnostic indicator and inhibits immune escape in triple-negative breast cancer].
    Chen T; Dong Y; Wu X
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2022 Apr; 38(4):347-356. PubMed ID: 35583065
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Current situation of programmed cell death protein 1/programmed cell death ligand 1 inhibitors in advanced triple-negative breast cancer.
    Liang Y; Liu X; Li K; Li H
    Chin J Cancer Res; 2022 Apr; 34(2):117-130. PubMed ID: 35685994
    [TBL] [Abstract][Full Text] [Related]  

  • 65. WBP2 Downregulation Inhibits Proliferation by Blocking YAP Transcription and the EGFR/PI3K/Akt Signaling Pathway in Triple Negative Breast Cancer.
    Song H; Wu T; Xie D; Li D; Hua K; Hu J; Fang L
    Cell Physiol Biochem; 2018; 48(5):1968-1982. PubMed ID: 30092563
    [TBL] [Abstract][Full Text] [Related]  

  • 66. D-mannose facilitates immunotherapy and radiotherapy of triple-negative breast cancer via degradation of PD-L1.
    Zhang R; Yang Y; Dong W; Lin M; He J; Zhang X; Tian T; Yang Y; Chen K; Lei QY; Zhang S; Xu Y; Lv L
    Proc Natl Acad Sci U S A; 2022 Feb; 119(8):. PubMed ID: 35181605
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Therapeutic cooperation between auranofin, a thioredoxin reductase inhibitor and anti-PD-L1 antibody for treatment of triple-negative breast cancer.
    Raninga PV; Lee AC; Sinha D; Shih YY; Mittal D; Makhale A; Bain AL; Nanayakarra D; Tonissen KF; Kalimutho M; Khanna KK
    Int J Cancer; 2020 Jan; 146(1):123-136. PubMed ID: 31090219
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Anti-cancer effect of a phytochemical compound - 7R-acetylmelodorinol - against triple-negative breast cancer cells.
    Thepmalee C; Sawasdee N; Jenkham P; Thephinlap C; Khoothiam K; Suwannasom N; Chokchaisiri R; Panya A; Yenchitsomanus PT
    Biomed Pharmacother; 2023 Oct; 166():115286. PubMed ID: 37573655
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Predictive biomarkers of response and survival following immunotherapy with a PD-L1 inhibitor benmelstobart (TQB2450) and antiangiogenic therapy with a VEGFR inhibitor anlotinib for pretreated advanced triple negative breast cancer.
    Han Y; Wang J; Sun T; Ouyang Q; Li J; Yuan J; Xu B
    Signal Transduct Target Ther; 2023 Nov; 8(1):429. PubMed ID: 37973901
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Inhibitory Effect of Hesperidin on the Expression of Programmed Death Ligand (PD-L1) in Breast Cancer.
    Kongtawelert P; Wudtiwai B; Shwe TH; Pothacharoen P; Phitak T
    Molecules; 2020 Jan; 25(2):. PubMed ID: 31936263
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Emerging strategies: PARP inhibitors in combination with immune checkpoint blockade in BRCA1 and BRCA2 mutation-associated and triple-negative breast cancer.
    Gupta T; Vinayak S; Telli M
    Breast Cancer Res Treat; 2023 Jan; 197(1):51-56. PubMed ID: 36318381
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Inhibition of autophagy by chloroquine prevents resistance to PI3K/AKT inhibitors and potentiates their antitumor effect in combination with paclitaxel in triple negative breast cancer models.
    Cocco S; Leone A; Roca MS; Lombardi R; Piezzo M; Caputo R; Ciardiello C; Costantini S; Bruzzese F; Sisalli MJ; Budillon A; De Laurentiis M
    J Transl Med; 2022 Jun; 20(1):290. PubMed ID: 35761360
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Combination of SF1126 and gefitinib induces apoptosis of triple-negative breast cancer cells through the PI3K/AKT-mTOR pathway.
    Deng M; Wang J; Chen Y; Zhang L; Liu D
    Anticancer Drugs; 2015 Apr; 26(4):422-7. PubMed ID: 25588160
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Programmed death-ligand 1 signaling and expression are reversible by lycopene via PI3K/AKT and Raf/MEK/ERK pathways in tongue squamous cell carcinoma.
    Peng M; Fan S; Li J; Zhou X; Liao Q; Tang F; Liu W
    Genes Nutr; 2022 Feb; 17(1):3. PubMed ID: 35164673
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Immunotherapy Targeting PD-1/PD-L1 in Early-Stage Triple-Negative Breast Cancer.
    Yang T; Li W; Huang T; Zhou J
    J Pers Med; 2023 Mar; 13(3):. PubMed ID: 36983708
    [TBL] [Abstract][Full Text] [Related]  

  • 76. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
    Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Therapeutic activity of DCC-2036, a novel tyrosine kinase inhibitor, against triple-negative breast cancer patient-derived xenografts by targeting AXL/MET.
    Shen Y; Zhang W; Liu J; He J; Cao R; Chen X; Peng X; Xu H; Zhao Q; Zhong J; Ding W; Lei X; Jiang Y; Zu X
    Int J Cancer; 2019 Feb; 144(3):651-664. PubMed ID: 30289981
    [TBL] [Abstract][Full Text] [Related]  

  • 78.
    Hirayama A; Ishigaki H; Takahashi K; Miura Y; Kikuchi H; Kubohara Y
    Juntendo Iji Zasshi; 2023; 69(2):105-115. PubMed ID: 38854456
    [TBL] [Abstract][Full Text] [Related]  

  • 79. JAK2 and PD-L1 Amplification Enhance the Dynamic Expression of PD-L1 in Triple-negative Breast Cancer.
    Chen M; Pockaj B; Andreozzi M; Barrett MT; Krishna S; Eaton S; Niu R; Anderson KS
    Clin Breast Cancer; 2018 Oct; 18(5):e1205-e1215. PubMed ID: 29933930
    [TBL] [Abstract][Full Text] [Related]  

  • 80. OSW-1 induces apoptosis and cyto-protective autophagy, and synergizes with chemotherapy on triple negative breast cancer metastasis.
    Wu M; Huang Q; Liao M; Wu X; Xi H; Ma H; Li S; Zhang Y; Xia Y
    Cell Oncol (Dordr); 2022 Dec; 45(6):1255-1275. PubMed ID: 36155886
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.